Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2025-07-02 Director's Dealing
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report insider transactions (purchases/sales of shares by directors or major shareholders). According to the provided definitions, 'Director's Dealing' (DIRS) covers reports of personal share transactions by company directors and executives, which matches the content of this filing.
2025-07-02 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Results of Treasury Stock Acquisition' (자기주식취득결과보고서) filed by Celltrion. It details the specific dates, quantities, and prices of shares repurchased by the company from the market. This falls directly under the definition of 'Transaction in Own Shares' (POS), which covers share buybacks.
2025-06-26 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Celltrion, specifically detailing a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This filing outlines the company's plan to buy back its own shares from the market to stabilize the stock price and enhance shareholder value. According to the provided definitions, documents reporting the company's buyback of its own shares are classified as 'Transaction in Own Shares' (POS).
2025-06-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory requirement for insiders (directors, executives, and major shareholders) to disclose changes in their shareholdings, commonly known as 'Director's Dealing' or 'Insider Trading' reports. Based on the provided categories, 'DIRS' (Director's Dealing) is the most accurate classification.
2025-06-24 Korean
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 신청(Part2))
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Celltrion regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of a Phase 3 clinical trial application (Part 2) to the European Medicines Agency (EMA). This is a standard corporate disclosure of a material event related to business operations and R&D progress. Since it does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the general regulatory filing category.
2025-06-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific executive (구윤모) at Celltrion. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2025-06-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.